Edgar Filing: Theravance Biopharma, Inc. - Form 4

Theravance I Form 4 June 05, 201	Biopharma, Inc. 4										
FORM	1 /								PPROVAL		
	4 UNITED	STATES		RITIES . shingtor			E COMMISSION	OMB Number:	3235-0287		
Check the if no long				Expires:	January 31 2005						
subject to Section 1 Form 4 o	6. SIAIE N	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
Form 5 obligation may cont <i>See</i> Instru 1(b).	ns inue. Section 17(a) of the l	Public U	Jtility Ho	lding Co		nge Act of 1934, a of 1935 or Section 1940	on			
(Print or Type F	Responses)										
1. Name and A JONKER JE	2. Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [TBPH				5. Relationship of Reporting Person(s) to Issuer						
	(First) (Middle)			-		(Check all applicable)				
(Last) THERAVA INC., 901 G	3. Date of Earliest Transaction (Month/Day/Year) 06/03/2014			Director 10% Owner X_ Officer (give title Other (specify below) Senior VP, Corp. & Bus. Dev.							
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line)					
SOUTH SA FRANCISC	N O, CA 94080		1 1100(111	Jilli Day 10			_X_ Form filed by	One Reporting P More than One R			
(City)	(State)	(Zip)	Tat	ole I - Non-	Derivative	Securities A	Acquired, Disposed o	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)		Date, if	Code	4. Securit onAcquired Disposed (Instr. 3,	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount		(Instr. 3 and 4)				
Reminder: Rep	ort on a separate line	e for each cl	ass of sec	urities bene	-	-	-				
					inforr requi	nation con red to resp ays a curre	spond to the collect tained in this form ond unless the for ntly valid OMB col	are not m	SEC 1474 (9-02)		
	Tab					sposed of, or convertible	Beneficially Owned securities)				

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	Dispo	rities ired (A) o osed of (D : 3, 4, and	f (D)		(Instr. 3 and 4)	
				Code	√ (A	A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 23.51	06/03/2014		А	123	,100	<u>(1)</u>	06/02/2024	Common Stock	123,100

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
JONKER JEFFREY DAVID THERAVANCE BIOPHARMA US, IN 901 GATEWAY BLVD. SOUTH SAN FRANCISCO, CA 94080			Senior VP, Corp. & Bus. Dev.					
Signatures								
Brett A. Grimaud, Attorney-in-Fact	06/05/2014							

<u>**Signature of Reporting Person</u> Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option shall vest and become exercisable as follows: (a) with respect to the first 25% of the Company's shares subject to the option on February 20, 2015, subject to the optionee's continuous service through such date and (b) with respect to an additional 1/48th of the

(1) Company's shares subject to the option when the optionee completes each month of continuous service thereafter. The option shall be fully vested and exercisable on February 20, 2018 provided the optionee remains in continuous service with the Company through such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.